Skip to main content
. Author manuscript; available in PMC: 2019 Feb 1.
Published in final edited form as: Cancer. 2017 Oct 17;124(3):537–545. doi: 10.1002/cncr.31072

Figure 2.

Figure 2

Figure 2

A. Kaplan-Meier curves of Progression Free Survival of CPB (carboplatin, paclitaxel, and bevacizumab) versus CPBE (carboplatin, paclitaxel, and bevacizumab plus everolimus)

B. Kaplan-Meier curves of Overall Survival of CPB (carboplatin, paclitaxel, and bevacizumab) versus CPBE (carboplatin, paclitaxel, and bevacizumab plus everolimus)